Home Blog Page 1708

Onward Therapeutics Completes Share Exchange and Establishes Global Headquarters in Taiwan

  • Following the group restructuring, Onward Therapeutics, Inc. serves as the global headquarters and holding company in Taiwan.
  • The existing Swiss and French subsidiaries maintain fully operational, focusing on preclinical and clinical development.
  • All licenses, IP rights, and ongoing R&D projects remain unchanged.

TAIPEI and LAUSANNE, Switzerland, Nov. 11, 2025 /PRNewswire/ — Onward Therapeutics today announced the completion of a share exchange, under which Onward Therapeutics, Inc. (Onward Taiwan) has become the group’s global holding and headquarters, while Onward Therapeutics SA (Onward Switzerland) has become a wholly owned subsidiary of Onward Taiwan.

The group reorganization involved the exchange of all shares in the former Swiss parent company for shares in the new Taiwan entity, maintaining ownership ratios and board composition. This milestone marks a strategic step in aligning Onward’s global operations and expanding its presence across Asia and Europe. The Taiwan entity brings together Onward’s scientific and corporate teams across Taiwan, Switzerland, and France under a unified corporate structure.

Over the past six years, Onward has built a robust pipeline of four innovative programs targeting both solid and hematologic tumors, through in-licensing, acquisition, and internal discovery. The group reorganization was designed to align Onward’s corporate structure with Taiwan’s dynamic biotechnology capital market and to support the company’s long-term growth plans, including future fundraising and potential public listing.

Building on its strong base of Taiwanese and multinational shareholders, Onward aims to leverage Taiwan’s scientific excellence, robust clinical trial infrastructure, and proven capabilities in advanced biopharmaceutical manufacturing to accelerate global development programs and partnerships. Taiwan’s supportive regulatory framework and innovation-driven investment environment further reinforce Onward’s ability to pursue sustainable growth and its role as an international enterprise.

Dr. C. Grace Yeh, Founder, Chairperson and CEO of Onward Therapeutics, stated “I am very grateful for the unanimous approval of the share exchange by all shareholders. Establishing our global headquarters in Taiwan represents both a symbolic and pragmatic achievement for Onward. Taiwan combines innovation, efficiency, and connectivity, the essential elements for the next stage of our global growth. With an outstanding scientific community and a strong investor base, Taiwan provides the ideal environment for Onward to expand its mission of developing transformative cancer therapies worldwide.”

About Onward Therapeutics

Onward Therapeutics (www.onward-therapeutics.com) is a clinical-stage biotechnology company dedicated to overcoming cancer resistance with novel and multi-modality therapies. Led by a seasoned team in translational science and drug development, the company advances promising candidates through a fast-track development model. Its portfolio includes a bispecific antibody (OT-A201) licensed from Biomunex Pharmaceuticals, alongside an equity investment, and an allogeneic NK cell therapy (OT-C001) developed via its majority-owned subsidiary, Emercell. Beyond these two lead clinical assets, the company is developing two first-in-class early development programs, including a small molecule in onco-metabolism (OT-S00X) licensed from Institut du Cancer de Montpellier, and an internal multi-specific antibody platform (OT-A30X). Founded in Switzerland, the company has established its global headquarters in Taiwan, reinforcing its integrated global operation across Taiwan, Switzerland, and France.

Onward Therapeutics Completes Share Exchange and Establishes Global Headquarters in Taiwan

  • Following the group restructuring, Onward Therapeutics, Inc. serves as the global headquarters and holding company in Taiwan.
  • The existing Swiss and French subsidiaries maintain fully operational, focusing on preclinical and clinical development.
  • All licenses, IP rights, and ongoing R&D projects remain unchanged.

TAIPEI and LAUSANNE, Switzerland, Nov. 11, 2025 /PRNewswire/ — Onward Therapeutics today announced the completion of a share exchange, under which Onward Therapeutics, Inc. (Onward Taiwan) has become the group’s global holding and headquarters, while Onward Therapeutics SA (Onward Switzerland) has become a wholly owned subsidiary of Onward Taiwan.

The group reorganization involved the exchange of all shares in the former Swiss parent company for shares in the new Taiwan entity, maintaining ownership ratios and board composition. This milestone marks a strategic step in aligning Onward’s global operations and expanding its presence across Asia and Europe. The Taiwan entity brings together Onward’s scientific and corporate teams across Taiwan, Switzerland, and France under a unified corporate structure.

Over the past six years, Onward has built a robust pipeline of four innovative programs targeting both solid and hematologic tumors, through in-licensing, acquisition, and internal discovery. The group reorganization was designed to align Onward’s corporate structure with Taiwan’s dynamic biotechnology capital market and to support the company’s long-term growth plans, including future fundraising and potential public listing.

Building on its strong base of Taiwanese and international long-term shareholders, Onward aims to leverage Taiwan’s scientific excellence, robust clinical trial infrastructure, and proven capabilities in advanced biopharmaceutical manufacturing to accelerate global development programs and partnerships. Taiwan’s supportive regulatory framework and innovation-driven investment environment further reinforce Onward’s ability to pursue sustainable growth and its role as a globally oriented enterprise.

Dr. C. Grace Yeh, Founder, Chairperson and CEO of Onward Therapeutics, stated “I am very grateful for the unanimous approval of the share exchange by all shareholders. Establishing our global headquarters in Taiwan represents both a symbolic and pragmatic achievement for Onward. Taiwan combines innovation, efficiency, and connectivity, the essential elements for the next stage of our global growth. With an outstanding scientific community and a strong investor base, Taiwan provides the ideal environment for Onward to expand its mission of developing transformative cancer therapies worldwide.”

About Onward Therapeutics

Onward Therapeutics (www.onward-therapeutics.com) is a clinical-stage biotechnology company dedicated to overcoming cancer resistance with novel and multi-modality therapies. Led by a seasoned team in translational science and drug development, the company advances promising candidates through a fast-track development model. Its portfolio includes a bispecific antibody (OT-A201) licensed from Biomunex Pharmaceuticals, alongside an equity investment, and an allogeneic NK cell therapy (OT-C001) developed via its majority-owned subsidiary, Emercell. Beyond these two lead clinical assets, the company is developing two first-in-class early development programs, including a small molecule in onco-metabolism (OT-S00X) licensed from Institut du Cancer de Montpellier, and an internal multi-specific antibody platform (OT-A30X). Founded in Switzerland, the company has established its global headquarters in Taiwan, reinforcing its integrated global operation across Taiwan, Switzerland, and France.

Diplomacy gets delicious: Consulate General of Italy partners with Aperol Spritz as the ‘Official Taste of Italian Summer’ Down Under

SYDNEY, Australia, Nov. 11, 2025 /PRNewswire/ — For the first time in Australia, the Italian Consulate General has partnered with Aperol, the number one cocktail in Italy, to share the official taste of Italian summer Down Under.

 

In a stately address alongside Jacopo Borsa, Managing Director for Australia at Campari Group Consul General, Gianluca Rubagotti officially recognised the iconic orange tipple as the perfect Aperitivo companion marking the launch of Italian Summer Down Under.

To celebrate the launch of Italian Summer Down Under, the Italian Consulate invited Aussies to raise an Aperol Spritz over the weekend. Taking summer to the streets of Sydney and Melbourne, a parade of Aperol waiters descended on the two cities offering complimentary Aperol Spritzes. The waiters were spotted at popular Sydney locations like Watsons Bay, Bondi Beach and Circular Quay while in Melbourne they travelled to St Kilda Pier, Federation Square and Hozier Lane.

The Consul General, Gianluca Rubagotti said: “The aperitif is more than a drink—it’s a ritual pause between a day’s work and night’s promise. Few capture this better than the Aperol Spritz. Its magic lies not just in the glass, but in the company, – picture it paired with a plate of prosciutto crudo di Parma o San Daniele, green Castelvetrano olives, and Parmigiano-Reggiano shards drizzled with aged balsamic vinegar from Modena. From Venice to Sydney, Aperol Spritz and its culinary companions remind us that summer is best served slowly, with flavour and friends.”

Jacopo Borsa, Managing Director – Australia at Campari Group, said: “Aperol is proud to be championing this aperitivo moment by bringing over a century of heritage and Italian flair to every glass. Partnering with the Italian Consulate General marks a cultural milestone: aperitivo is no longer just a taste of Italy, it’s becoming part of the Australian summer lifestyle.”

For those looking to get a flavour of Italy this summer; slow living, long lunches, and Aperitivo culture, consider this your sign to enjoy the sun on your back and bask in the glow of Italian summer right here in Australia.

Keep an eye on Aperol Spritz Australia’s social channels to stay in the know a find out why Aperol Spritz is one of the most searched for cocktails worldwide! @aperolspritzau

About Campari Group

Davide Campari-Milano N.V., together with its affiliates (“Campari Group”), is a major player in the global beverage sector, trading in over 190 nations around the world with leading positions in Europe and the Americas. Campari Group was founded in 1860 and today is the sixth-largest player worldwide in the premium spirits industry. Campari Group’s portfolio, with over 50 brands, spans spirits (the core business), wines, and soft drinks. Its internationally renowned brands include Aperol®, Appleton Estate®, Campari®, SKYY®, Wild Turkey®, and Grand Marnier®. Headquartered in Sesto San Giovanni, Italy, Campari Group owns 22 plants worldwide and has its own distribution network in 22 countries. Campari Group employs around 4,000 people. The shares of the parent company, Davide Campari-Milano N.V. (Reuters CPRI.MI – Bloomberg CPR IM), have been listed on the Italian Stock Exchange since 2001. For more information: www.camparigroup.com. Please enjoy our brands responsibly. 

Campari Group is a contributor to DrinkWise Australia, an independent, not-for-profit organisation focusing on helping to bring about a healthier and safer drinking culture in Australia. Please see more information on https://drinkwise.org.au/  

Please enjoy our brands responsibly. 

 

Yalla Group Limited Announces Unaudited Third Quarter 2025 Financial Results

DUBAI, UAE, Nov. 11, 2025 /PRNewswire/ — Yalla Group Limited (“Yalla” or the “Company”) (NYSE: YALA), the largest Middle East and North Africa (MENA)-based online social networking and gaming company, today announced its unaudited financial results for the third quarter ended September 30, 2025.

Third Quarter 2025 Financial and Operating Highlights

  • Revenues were US$89.6 million in the third quarter of 2025, representing an increase of 0.8% from the third quarter of 2024.
    • Revenues generated from chatting services in the third quarter of 2025 were US$55.5 million.
    • Revenues generated from games services in the third quarter of 2025 were US$33.8 million.
  • Net income was US$40.7 million in the third quarter of 2025, a 3.9% increase from US$39.2 million in the third quarter of 2024. Net margin[1] was 45.4% in the third quarter of 2025.
  • Non-GAAP net income[2] was US$43.1 million in the third quarter of 2025, a 1.2% increase from US$42.6 million in the third quarter of 2024. Non-GAAP net margin[3] was 48.1% in the third quarter of 2025.
  • Average MAUs[4] increased by 8.1% to 43.4 million in the third quarter of 2025, from 40.2 million in the third quarter of 2024.
  • The number of paying users[5] on our platform decreased by 9.7% to 11.4 million in the third quarter of 2025, from 12.6 million in the third quarter of 2024.

Key Operating Data

For the three months ended

September 30, 2024

September 30, 2025

Average MAUs (in thousands)

40,176

43,420

Paying users (in thousands)

12,582

11,366

 

[1] Net margin is net income as a percentage of revenues.

[2] Non-GAAP net income represents net income excluding share-based compensation. Non-GAAP net income is a non-GAAP financial measure. See the sections entitled “Non-GAAP Financial Measures” and “Reconciliations of GAAP and Non-GAAP Results” for more information about the non-GAAP measures referred to in this press release.

[3] Non-GAAP net margin is non-GAAP net income as a percentage of revenues.

[4] “Average MAUs” refers to the average monthly active users in a given period, calculated by dividing (i) the sum of active users for each month of such period by (ii) the number of months in such period. “Active users” refers to registered users who accessed any of our main mobile applications at least once during a given period.

[5] “Paying users” refers to registered users who played a game or purchased our virtual items or upgraded services using virtual currencies on our main mobile applications at least once in a given period, except for users who received all of their virtual currencies directly or indirectly from us for free. “Registered users” refers to users who have registered accounts on our main mobile applications as of a given time; a registered user is not necessarily a unique user, as an individual may register multiple accounts on our main mobile applications.

“We’re pleased to deliver a strong set of results for the third quarter of 2025,” said Mr. Tao Yang, Founder, Chairman and CEO of Yalla. “Our revenues reached US$89.6 million, once again beating the high end of our guidance. Our dedication to enhancing operational efficiency continued to pay off, with net margin increasing by 1.4 percentage points year-over-year to 45.4%. We also continued to optimize our product portfolio and enhance user engagement, driving an 8.1% year-over-year increase in average MAUs to 43.4 million.

“Our thriving game pipeline served as our primary market expansion driver during the third quarter. We soft-launched our first match-3 title, Turbo Match, on Android during the quarter, and we were pleased to see its initial user acquisition and retention metrics meeting our expectations. We also expect to debut our self-developed roguelike game and an SLG game in collaboration with an industry-leading gaming studio in the coming weeks, deepening our penetration of MENA’s mid- and hard-core game market.

“Yalla Group celebrated the fifth anniversary of its IPO with a bell-ringing ceremony at NYSE in September, a proud symbol of our years of growth, learning, persistence, and achievement. Going forward, we will remain dedicated to maximizing the synergy between our social and gaming ecosystems and enhancing our AI-fueled technological edge, bringing us ever closer to our vision of becoming the most popular platform for online social networking and entertainment activities in MENA,” Mr. Yang concluded.

Ms. Karen Hu, CFO of Yalla, commented, “In the third quarter, we continued to pursue high-quality growth and profitability enhancement. Excellent execution of our ongoing cost management and efficiency improvement initiatives, including AI development and application, drove an increase in our net income to US$40.7 million. Supported by these healthy results and our robust fundamentals, we continued to return value to shareholders. As of November 7, 2025, we had returned a total of US$51.9 million to shareholders in 2025 through our share repurchase program. We will continue to deepen our commitment to shareholder returns, and look forward to completing our current US$150 million share repurchase program within the next year, delivering sustainable, long-term value to all stakeholders.”

Third Quarter 2025 Financial Results

Revenues                                                                                                      

Our revenues were US$89.6 million in the third quarter of 2025, a 0.8% increase from US$88.9 million in the third quarter of 2024. The increase was primarily driven by our broadening user base and enhanced monetization capability.

In the third quarter of 2025, revenues generated from chatting services were US$55.5 million, and revenues from games services were US$33.8 million.

Costs and expenses

Our total costs and expenses were US$55.9 million in the third quarter of 2025, a 1.0% decrease from US$56.4 million in the third quarter of 2024.

Our cost of revenues was US$28.4 million in the third quarter of 2025, a 10.7% decrease from US$31.8 million in the third quarter of 2024, primarily due to lower commission fees paid to third-party payment platforms as a result of diversified payment channels and lower share-based compensation expenses recognized in the third quarter of 2025. Cost of revenues as a percentage of our total revenues decreased to 31.7% in the third quarter of 2025 from 35.8% in the third quarter of 2024.

Our selling and marketing expenses were US$9.6 million in the third quarter of 2025, a 30.3% increase from US$7.4 million in the third quarter of 2024, primarily due to higher advertising and market promotion expenses attributable to our continued user acquisition efforts and expanding product portfolio. Selling and marketing expenses as a percentage of our total revenues increased to 10.7 % in the third quarter of 2025 from 8.3% in the third quarter of 2024.

Our general and administrative expenses were US$9.2 million in the third quarter of 2025, a 9.0% decrease from US$10.1 million in the third quarter of 2024, primarily due to a decrease in incentive compensation and professional service fees. General and administrative expenses as a percentage of our total revenues decreased to 10.3% in the third quarter of 2025 from 11.4% in the third quarter of 2024.

Our technology and product development expenses were US$8.6 million in the third quarter of 2025, a 21.4% increase from US$7.1 million in the third quarter of 2024, primarily due to an increase in salaries and benefits for our technology and product development staff, driven by an increase in the headcount to support the development of new businesses and expansion of our product portfolio. Technology and product development expenses as a percentage of our total revenues increased to 9.6% in the third quarter of 2025 from 8.0% in the third quarter of 2024.

Operating income

Operating income was US$33.8 million in the third quarter of 2025, a 3.9% increase from US$32.5 million in the third quarter of 2024.

Non-GAAP operating income[6]

Non-GAAP operating income in the third quarter of 2025 increased to US$36.2 million, a 0.7% increase from US$35.9 million in the third quarter of 2024.

Interest income

Interest income was US$6.3 million in the third quarter of 2025, compared with US$7.8 million in the third quarter of 2024.

Investment income

Investment income was US$2.2 million in the third quarter of 2025, compared with US$0.1 million in the third quarter of 2024, primarily due to increased investments in wealth management products.

Income tax expense

Income tax expense was US$1.6 million in the third quarter of 2025, compared with US$1.3 million in the third quarter of 2024.

Net income

As a result of the foregoing, our net income was US$40.7 million in the third quarter of 2025, a 3.9% increase from US$39.2 million in the third quarter of 2024.

Non-GAAP net income

Non-GAAP net income in the third quarter of 2025 was US$43.1 million, a 1.2% increase from US$42.6 million in the third quarter of 2024.

Earnings per ordinary share

Basic and diluted earnings per ordinary share were US$0.27 and US$0.23, respectively, in the third quarter of 2025, while basic and diluted earnings per ordinary share were US$0.25 and US$0.22, respectively, in the third quarter of 2024.

Non-GAAP earnings per ordinary share[7]

Non-GAAP basic and diluted earnings per ordinary share were US$0.28 and US$0.24, respectively, in the third quarter of 2025, compared with US$0.27 and US$0.24, respectively, in the third quarter of 2024.

Cash and cash equivalents, restricted cash, term deposits and short-term investments 

As of September 30, 2025, we had cash and cash equivalents, restricted cash, term deposits and short-term investments of US$739.5 million, compared with US$656.3 million as of December 31, 2024.

Share repurchase program

Pursuant to the Company’s share repurchase program beginning on May 21, 2021, with an extended expiration date of May 21, 2026, from January 1 through November 7, 2025, the Company repurchased 7,716,483 American depositary shares (“ADSs”), representing 7,716,483 Class A ordinary shares, from the open market with cash for an aggregate amount of approximately US$51.9 million. As of November 7, 2025, the Company had cumulatively completed cash repurchases in the open market of 15,021,621 ADSs, representing 15,021,621 Class A ordinary shares, for an aggregate amount of approximately US$101.4 million, since the inception of the current share repurchase program. The aggregate value of ADSs and/or Class A ordinary shares that remain available for purchase under the current share repurchase program was US$48.6 million as of November 7, 2025. In addition, the Company has decided to cancel all shares repurchased in 2025. As of August 11, 2025, the Company had cancelled 6,230,299 ADSs, representing 6,230,299 Class A ordinary shares.

Outlook

For the fourth quarter of 2025, Yalla currently expects revenues to be between US$78.0 million and US$85.0 million.

The above outlook is based on current market conditions and reflects the Company management’s current and preliminary estimates of market and operating conditions and customer demand, which are all subject to change.

[6] Non-GAAP operating income represents operating income excluding share-based compensation. Non-GAAP operating income is a non-GAAP financial measure. See the sections entitled “Non-GAAP Financial Measures” and “Reconciliations of GAAP and Non-GAAP Results” for more information about the non-GAAP measures referred to in this press release.       

[7] Non-GAAP earnings per ordinary share is non-GAAP net income attributable to Yalla Group Limited’s shareholders, divided by weighted average number of basic and diluted shares outstanding. Non-GAAP net income attributable to Yalla Group Limited’s shareholders represents net income attributable to Yalla Group Limited’s shareholders, excluding share-based compensation. Non-GAAP earnings per ordinary share and non-GAAP net income attributable to Yalla Group Limited’s shareholders are non-GAAP financial measures. See the sections entitled “Non-GAAP Financial Measures” and “Reconciliations of GAAP and Non-GAAP Results” for more information about the non-GAAP measures referred to in this press release.

Conference Call

The Company’s management will host an earnings conference call on Monday, November 10, 2025, at 8:00 PM U.S. Eastern Time, which is Tuesday, November 11, 2025, at 5:00 AM Dubai Time, or Tuesday, November 11, 2025, at 9:00 AM Beijing/Hong Kong time.

Dial-in details for the earnings conference call are as follows:

United States Toll Free:

+1-888-317-6003

International:

+1-412-317-6061

United Arab Emirates Toll Free:

80-003-570-3598

Mainland China Toll Free:

400-120-6115

Hong Kong, China Toll Free:

800-963-976

Access Code:

4820370

Additionally, a live and archived webcast of the conference call will be available on the Company’s investor relations website at https://ir.yalla.com

A replay of the conference call will be accessible until November 17, 2025, by dialing the following telephone numbers:

United States Toll Free:

+1-855-669-9658

International:

+1-412-317-0088

Access Code:

5560759

Non-GAAP Financial Measures

To supplement the financial measures prepared in accordance with generally accepted accounting principles in the United States, or GAAP, this press release presents non-GAAP financial measures, namely non-GAAP operating income, non-GAAP net income, non-GAAP net margin and non-GAAP basic and diluted earnings per ordinary share, as supplemental measures to review and assess the Company’s operating performance. The presentation of the non-GAAP financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with U.S. GAAP. We define non-GAAP operating income as operating income excluding share-based compensation. We define non-GAAP net income as net income excluding share-based compensation. We define non-GAAP net margin as non-GAAP net income as a percentage of revenues. We define non-GAAP net income attributable to Yalla Group Limited’s shareholders as net income attributable to Yalla Group Limited’s shareholders, excluding share-based compensation. We define non-GAAP earnings per ordinary share as non-GAAP net income attributable to Yalla Group Limited’s shareholders, divided by the weighted average number of basic and diluted shares outstanding.

By excluding the impact of share-based compensation expenses, which are non-cash charges, the Company believes that the non-GAAP financial measures help identify underlying trends in its business and enhance the overall understanding of the Company’s past performance and future prospects. Investors can better understand the Company’s operating and financial performance, compare business trends among different reporting periods on a consistent basis and assess its core operating results, as they exclude share-based compensation expenses, which are not expected to result in cash payments. The Company also believes that the non-GAAP financial measures allow for greater visibility with respect to key metrics used by the Company’s management in its financial and operational decision-making.

The non-GAAP financial measure is not defined under U.S. GAAP and is not presented in accordance with U.S. GAAP. The non-GAAP financial measure has limitations as analytical tools. One of the key limitations of using the non-GAAP financial measures is that they do not reflect all items of income and expense that affect the Company’s operations. Share-based compensation has been and may continue to be incurred in the Company’s business and is not reflected in the presentation of non-GAAP financial measures. Further, the non-GAAP financial measure may differ from the non-GAAP information used by other companies, including peer companies, and therefore their comparability may be limited.

The Company compensates for these limitations by providing the relevant disclosure of its non-GAAP financial measures in the reconciliations to the nearest U.S. GAAP performance measures, all of which should be considered when evaluating its performance. The Company encourages investors and others to review its financial information in its entirety and not rely on a single financial measure.

Reconciliations of GAAP and non-GAAP results are set forth at the end of this press release.

About Yalla Group Limited

Yalla Group Limited is the largest MENA-based online social networking and gaming company, in terms of revenues in 2022. The Company operates two flagship mobile applications, Yalla, a voice-centric group chat platform, and Yalla Ludo, a casual gaming application featuring online versions of board games, popular in MENA, with in-game voice chat and localized Majlis functionality. Building on the success of Yalla and Yalla Ludo, the Company continues to add engaging new content, creating a regionally-focused, integrated ecosystem dedicated to fulfilling MENA users’ evolving online social networking and gaming needs. Through its holding subsidiary, Yalla Game Limited, the Company has expanded its capabilities in mid-core and hard-core games in the MENA region, leveraging its local expertise to bring innovative gaming content to its users. In addition, the growing Yalla ecosystem includes YallaChat, an IM product tailored for Arabic users, WeMuslim, a product that supports Arabic users in observing their customs, and casual games such as Yalla Baloot and 101 Okey Yalla, developed to sustain vibrant local gaming communities in MENA. Yalla is also actively exploring outside of MENA with Yalla Parchis, a Ludo game designed for the South American markets. Yalla’s mobile applications deliver a seamless experience that fosters a sense of loyalty and belonging, establishing highly devoted and engaged user communities through close attention to detail and localized appeal that profoundly resonates with users.

For more information, please visit: https://ir.yalla.com.

Safe Harbor Statement

This press release contains statements that may constitute “forward-looking” statements pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “likely to” and similar statements. Statements that are not historical facts, including statements about Yalla Group Limited’s beliefs, plans and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. Further information regarding these and other risks is included in Yalla Group Limited’s filings with the SEC. All information provided in this press release is as of the date of this press release, and Yalla Group Limited does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

For investor and media inquiries, please contact:

Yalla Group Limited
Investor Relations
Kerry Gao – IR Director
Tel: +86-571-8980-7962
Email: ir@yalla.com 

Piacente Financial Communications
Jenny Cai
Tel: +86-10-6508-0677
Email: yalla@tpg-ir.com 

In the United States:

Piacente Financial Communications
Brandi Piacente
Tel: +1-212-481-2050
Email: yalla@tpg-ir.com 

 

 

 

YALLA GROUP LIMITED

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

As of

December 31,
2024

September 30,
2025

US$

US$

ASSETS

Current assets

Cash and cash equivalents

488,379,894

422,572,636

Restricted cash

1,975,616

1,645,579

Term deposits

94,983,813

84,800,000

Short-term investments

70,932,713

230,514,582

Prepayments and other current assets

35,429,988

31,913,969

Total current assets

691,702,024

771,446,766

Non-current assets

Property and equipment, net

13,962,393

14,440,027

Intangible asset, net

896,005

748,040

Operating lease right-of-use assets

1,370,914

1,082,968

Long-term investments

93,698,924

81,737,548

Total non-current assets

109,928,236

98,008,583

Total assets

801,630,260

869,455,349

LIABILITIES

Current liabilities

Accounts payable

957,717

781,364

Deferred revenue, current

58,081,649

55,446,794

Operating lease liabilities, current

1,012,481

232,331

Amounts due to a related party

87,156

57,940

Income taxes payable

9,117,261

2,414,471

Accrued expenses and other current liabilities

32,404,872

28,029,561

Total current liabilities

101,661,136

86,962,461

Non-current liabilities

Deferred revenue, non-current

2,173,826

Operating lease liabilities, non-current

13,495

257,128

Deferred tax liabilities

2,148,022

2,704,619

Total non-current liabilities

2,161,517

5,135,573

Total liabilities

103,822,653

92,098,034

EQUITY

Shareholders’ equity of Yalla Group Limited

Class A Ordinary Shares

14,064

13,441

Class B Ordinary Shares

2,473

2,473

Additional paid-in capital

328,883,061

336,882,266

Treasury stock

(49,438,661)

(34,635,502)

Accumulated other comprehensive loss

(3,016,579)

(2,396,947)

Retained earnings

427,907,766

485,401,009

Total shareholders’ equity of Yalla Group Limited

704,352,124

785,266,740

Non-controlling interests

(6,544,517)

(7,909,425)

Total equity

697,807,607

777,357,315

Total liabilities and equity

801,630,260

869,455,349

 

 

 

YALLA GROUP LIMITED

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS

OF OPERATIONS

Three Months Ended

Nine Months Ended

September 30,
2024

June 30,
2025

September 30,
2025

September 30,
2024

September 30,
2025

US$

US$

US$

US$

US$

Revenues

88,922,031

84,564,086

89,636,333

248,848,091

258,077,186

Costs and expenses

Cost of revenues

(31,830,126)

(27,944,596)

(28,430,988)

(89,427,060)

(85,576,007)

Selling and marketing expenses

(7,352,820)

(8,661,573)

(9,582,434)

(23,944,276)

(25,187,275)

General and administrative expenses

(10,133,394)

(9,002,347)

(9,224,448)

(24,358,190)

(26,922,103)

Technology and product development expenses

(7,108,024)

(8,338,195)

(8,629,226)

(19,851,894)

(24,795,558)

Total costs and expenses

(56,424,364)

(53,946,711)

(55,867,096)

(157,581,420)

(162,480,943)

Operating income

32,497,667

30,617,375

33,769,237

91,266,671

95,596,243

Interest income

7,829,223

6,791,492

6,300,342

21,572,082

19,653,014

Government grants

7,603

603,115

63,629

439,966

730,177

Investment income (loss)

133,606

21,758

2,204,831

(1,094,288)

2,208,887

Income before income taxes

40,468,099

38,033,740

42,338,039

112,184,431

118,188,321

Income tax expense

(1,287,156)

(1,531,310)

(1,613,621)

(10,563,946)

(4,582,008)

Net income

39,180,943

36,502,430

40,724,418

101,620,485

113,606,313

Net loss attributable to non-controlling interests

673,856

269,782

386,428

1,472,271

1,368,145

Net income attributable to Yalla Group
   Limited’s shareholders

39,854,799

36,772,212

41,110,846

103,092,756

114,974,458

Earnings per ordinary share

——Basic

0.25

0.24

0.27

0.64

0.73

——Diluted

0.22

0.20

0.23

0.56

0.64

Weighted average number of shares
   outstanding used in computing earnings
   per ordinary share

——Basic

160,944,036

155,958,658

154,491,280

160,681,773

156,555,683

——Diluted

183,354,110

180,765,359

179,310,959

183,383,311

180,764,819

Share-based compensation was allocated in cost of revenues, selling and marketing expenses, general and administrative expenses and technology and product development expenses as follows:

Three Months Ended

Nine Months Ended

September 30,
2024

June 30,
2025

September 30,
2025

September 30,
2024

September 30,
2025

US$

US$

US$

US$

US$

Cost of revenues

1,867,294

1,328,152

1,143,119

5,637,874

3,797,356

Selling and marketing expenses

261,825

170,304

131,359

1,642,975

472,691

General and administrative expenses

1,114,753

1,328,931

1,073,416

3,769,267

3,532,854

Technology and product development expenses

187,205

20,670

56,160

469,134

196,304

Total share-based compensation expenses

3,431,077

2,848,057

2,404,054

11,519,250

7,999,205

 

 

 

YALLA GROUP LIMITED

RECONCILIATIONS OF GAAP AND NON-GAAP RESULTS

Three Months Ended

Nine Months Ended

September 30,
2024

June 30,
2025

September 30,
2025

September 30,
2024

September 30,
2025

US$

US$

US$

US$

US$

Operating income

32,497,667

30,617,375

33,769,237

91,266,671

95,596,243

Share-based compensation expenses

3,431,077

2,848,057

2,404,054

11,519,250

7,999,205

Non-GAAP operating income

35,928,744

33,465,432

36,173,291

102,785,921

103,595,448

Net income

39,180,943

36,502,430

40,724,418

101,620,485

113,606,313

Share-based compensation expenses,
   net of tax effect of nil

3,431,077

2,848,057

2,404,054

11,519,250

7,999,205

Non-GAAP net income

42,612,020

39,350,487

43,128,472

113,139,735

121,605,518

Net income attributable to Yalla
   Group Limited’s shareholders

39,854,799

36,772,212

41,110,846

103,092,756

114,974,458

Share-based compensation expenses,
   net of tax effect of nil

3,431,077

2,848,057

2,404,054

11,519,250

7,999,205

Non-GAAP net income attributable to
   Yalla Group Limited’s shareholders

43,285,876

39,620,269

43,514,900

114,612,006

122,973,663

Non-GAAP earnings per ordinary share

——Basic

0.27

0.25

0.28

0.71

0.79

——Diluted

0.24

0.22

0.24

0.62

0.68

Weighted average number of shares
   outstanding used in computing earnings
   per ordinary share

——Basic

160,944,036

155,958,658

154,491,280

160,681,773

156,555,683

——Diluted

183,354,110

180,765,359

179,310,959

183,383,311

180,764,819

 

Vexev’s VxWave System Successfully Meets Clinical Endpoints in Landmark Study Evaluating Robotic Ultrasound Scanning for Mapping Vascular Access at U.S. Renal Care Dialysis Clinics

  • VxWave Ultrasound Imaging System demonstrated 94% scanning success rate and 100% data adequacy rate for vascular access creation strategies in CANSCAN trial
  • New insights into vascular anatomy made possible by standardized image acquisition and reporting
  • VxWave System has the potential to significantly advance standardization of vascular assessment at the point of care

SYDNEY and SAN ANTONIO, Nov. 11, 2025 /PRNewswire/ — Vexev, an Australian-based medical device company advancing next-generation vascular imaging, and U.S. Renal Care, a leading provider of in-center and home dialysis in the United States, announced the highly successful results of the CANSCAN Trial (NCT06691672), providing evidence that the VxWave Ultrasound Imaging System can reliably perform semi-autonomous vascular mapping examinations directly within the dialysis clinic. Dr. Varshi Broumand, CANSCAN Study Principal Investigator, presented the results during the American Society of Nephrology’s annual meeting, Kidney Week 2025, in Houston, Texas (November 5-9).

“Functioning vascular access is a lifeline for patients on hemodialysis, yet nearly 3 out of 4 arteriovenous fistulas (AVF) fail to mature or are abandoned before use. While traditional vascular mapping scans have improved vascular access, they suffer from poor patient compliance due to being scheduled outside of dialysis appointments, often lack standardized quality and are expensive,” explained Dr. Broumand, Interventional Nephrologist at South Texas Renal Care Group. “The CANSCAN Trial highlights the potential that with the robotic VxWave System, we can finally bring high-quality vascular imaging on-demand in the dialysis clinic, overcoming barriers of cost, compliance, and variability that have limited patient outcomes for far too long.”

The first-of-its-kind, multi-center feasibility trial scanned 115 patients with severe kidney damage or end stage renal disease (CKD stage 4 and 5 patients) and the primary endpoints demonstrated:

  • 94% Scan Completion Rate (SCR)
  • 100% Data Adequacy Rate (DAR)1
  • 98% of Access Options2 determined feasible in patients

The VxWave System is a robotic tomographic ultrasound imaging system specifically designed for upper limb vascular imaging to be delivered on-demand at the point of care. The system integrates advanced robotics, machine learning and ultrasound signal processing to create a 3D vascular model and detailed report that aims to provide insights into vascular access points for hemodialysis.

“The success of the CANSCAN Trial confirms that standardized, high-quality, point-of-care vascular assessment may now be achievable,” said Shannon Thomas, MD, Chief Medical Officer, Vexev. “The trial represents a significant step towards the future of standardized vascular assessment across the globe, allowing us to plan vascular access for hemodialysis with data-driven precision, especially for higher risk patients whose anatomical factors may complicate traditional planning.”

Beyond providing evidence of feasibility, the CANSCAN trial provided insights into the upper limb vascular anatomy of CKD stage 4 and 5 patients and identified subgroups who may be at a disadvantage for vascular access creation. Specifically, patients with diabetes had significantly more calcification in the upper limb arteries and a reduction in forearm distal vascular diameters. Furthermore, female patients were found to have statistically fewer available veins and smaller veins overall compared to males.

The VxWave system’s potential ability to standardize examinations would allow dialysis clinics to better determine subgroups who may be at a disadvantage for vascular access creation, ultimately aiming to reduce the high rates of access failure and dialysis dysfunction currently experienced by patients.

“This is one of the more promising innovations we’ve seen recently, and the results are encouraging,” said Geoff Block, MD, FASN, Associate Chief Medical Officer and Senior Vice President, Clinical Research & Medical Affairs for U.S. Renal Care. “They suggest real potential to improve patient outcomes. As access expands, we’re interested to see how an automated point-of-care imaging approach can enhance care across our network.” 

About Vexev
Vexev is an Australian med‑tech startup founded in 2018 by Dr. John Carroll and Dr. Eamonn Colley, experts in vascular fluid dynamics and computational imaging, dedicated to transforming blood-flow research into technology that improves vascular and renal health outcomes. Vexev is on a mission to improve lives by developing the next generation of vascular imaging solutions. Visit Vexev.com to learn more.

About U.S. Renal Care
U.S. Renal Care, the fastest-growing dialysis provider in the nation, partners with nephrologists across 32 states in the U.S. to care for more than 36,000 people living with kidney disease. Since 2000, U.S. Renal Care has been a leader in clinical quality, innovation, and operational excellence – delivering the best experience and outcomes for our patients. Visit USRenalCare.com to learn more.

1 The image quality of all successful scans was reviewed and deemed adequate by an independent panel of more than two vascular access specialists.
2 Access options include arteriovenous graft (AVG) or arteriovenous fistula (AVF)

Logo – https://laotiantimes.com/wp-content/uploads/2025/11/vexev_logo.jpg

Health In Tech Announces Third Quarter 2025 Financial Results

  • Revenue reached $8.5 million, up 90% year over year; nine-month revenue totaled $25.8 million, representing 132% of full-year 2024 total revenue.
  • Adjusted EBITDA was $1.0 million, an increase of 49% year over year; nine-month adjusted EBITDA reached $3.8 million, or 167% of full-year 2024 total.

STUART, Fla., Nov. 11, 2025 /PRNewswire/ — Health In Tech (Nasdaq: HIT), an Insurtech platform company backed by third-party AI technology, today announced its financial results for the third quarter ended September 30, 2025.

Financial Highlights for the Third Quarter and Nine-Month of 2025:

  • Billed Enrolled Employees. The number of billed enrolled employees (EEs) was 25,248, an increase of 7,654 EEs YoY.
  • Distribution. The number of Brokers, Third-party Administrator (“TPAs”) and Agencies expanded to 849 partners as of September 30, 2025, up 57% YoY.
  • Revenues. Total revenues were $8.5 million, up 90% YoY; The first-nine months revenues of $25.8 million, 132% of full year 2024.
  • Pre-tax income. Pre-tax income was $0.6 million, up 48% YoY; The first-nine months pre-tax income of $2.1 million, 238% of full year 2024.
  • Adjusted EBITDA. Adjusted EBITDA was $1.0 million, up 49% YoY; The first-nine months adjusted EBITDA of $3.8 million, 167% of full year 2024.
  • Cash. Cash balance was $8.0 million as of September 30, 2025.
  • Accounts receivable, net. Accounts receivable balance was $0.9 million as of September 30, 2025, reduced $0.1 million YoY.

Tim Johnson, CEO of Health In Tech, said:
“Our third quarter highlights the accelerating strength of our distribution ecosystem and the solid foundation we’ve built this year. Revenue reached $8.5 million, up 90% year over year, bringing nine-month revenue to $25.8 million—already 132% of full-year 2024 revenue. This growth reflects the continued expansion of our broker, TPA, and agency network, which is now translating directly into sustained revenue momentum as our technology gains adoption across new distribution channels.”

He continued:
“In September, we launched large-employer underwriting within eDIYBS, allowing brokers to generate quotes for groups of 150 or more employees in as little as two weeks—versus the industry timeline of often three months. This capability is a significant milestone, extending the speed and scalability of our small-business underwriting into the mid- and large-employer market. It marks a major step forward in how health plans are designed, quoted, and delivered at scale.”

Mr. Johnson added:
“We also remain focused on solving one of the most costly inefficiencies in U.S. healthcare—claims administration, which costs the industry more than $300 billion annually. Our non-binding LOI with AlphaTON Capital marks a strategic step toward exploring blockchain-enabled solutions that can modernize this process. Together with AlphaTON and Brittany Kaiser’s leadership in blockchain ethics and policy, we’re developing HITChain—a decentralized, verifiable claims infrastructure designed to compress processing timelines, eliminate duplication, lower costs, and create a transparent system of record for all stakeholders.

By combining insurance domain expertise with blockchain innovation, we’re seeking to position Health In Tech at the frontier of decentralized healthcare infrastructure—a market opportunity of substantial scale and long-term impact.”

“We delivered another quarter of strong financial performance,” said Julia Qian, CFO of Health In Tech. “Revenue grew 90% year over year and profit increased 48%, reflecting both operational strength and disciplined execution. We continue to balance growth with strategic investments in technology and enhanced platform capabilities—initiatives that reinforce our leadership position and support sustainable long-term performance.”

Recent Business Developments and Highlights

  • eDIYBS Upgrade: Expanded HIT’s Enhanced Do-It-Yourself Benefit System to serve 150+ employee groups. This upgrade significantly increases HIT’s addressable market and accelerates large-group underwriting from months to about 2 weeks, extending the speed and scalability of our small-business underwriting into the mid- and large-employer market. It marks a major step forward in how health plans are designed, quoted, and delivered at scale.

  • AlphaTON Capital: Signed a non-binding strategic LOI to co-develop HITChain, a blockchain-powered claims platform built on The Open Network (TON). The partnership positions HIT at the forefront of decentralized claims infrastructure, targeting efficiency gains in the $300B+ U.S. claims market.
  • 2026 Davos Summit: Announced to host HIT’s first Independent InsurTech Summit during the World Economic Forum week in Davos. The event will convene global leaders across insurance, healthcare, and technology. Two panels have been announced this quarter: “AI and Institutional Resistance – CEOs Driving Change in Legacy Sectors,” featuring TIME CEO Jessica Sibley and HIT CEO Tim Johnson; and “First Ladies: Backing Women Who Build” featuring Cherie Blair CBE, KC, Founder of the Cherie Blair Foundation for Women. Additional panels will be announced in the coming months, highlighting HIT’s expanding influence in shaping global industry dialogue.
  • SIIA 2025 Conference: Showcased upgraded eDIYBS to thousands of industry leaders. The event expanded broker engagement and reinforced HIT’s reputation as a leader in AI-powered self-funding solutions, demonstrating real-time quoting capabilities and platform flexibility.

Conference Call Details

Health In Tech will host a conference call to discuss the financial results for the Third quarter of 2025 on Nov 10, 2025, at 5:00 p.m. (ET). To participate in our live conference call and webcast, please dial 1-888-346-8982 or 1-412-902-4272 (for international participants).

A live audio webcast will be available via the Investor Relations page of Health In Tech’s website at https://healthintech.com/. A replay of the webcast will be available for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.

Non-GAAP Financial Information

This release presents Adjusted EBITDA, a non-GAAP financial metric, which is provided as a complement to the results provided in accordance with accounting principles generally accepted in the United States of America (“GAAP”). A reconciliation of historical non-GAAP financial information to the most directly comparable GAAP financial measure is provided in the accompanying tables found at the end of this release.

Use of ForwardLooking Statements

Certain statements in this press release are forward-looking statements for purposes of the safe harbor provisions under the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may include estimates or expectations about Health In Tech’s possible or assumed operational results, financial condition, business strategies and plans, market opportunities, competitive position, industry environment, and potential growth opportunities. In some cases, forward-looking statements can be identified by terms such as “may,” “will,” “should,” “design,” “target,” “aim,” “hope,” “expect,” “could,” “intend,” “plan,” “anticipate,” “estimate,” “believe,” “continue,” “predict,” “project,” “potential,” “goal,” or other words that convey the uncertainty of future events or outcomes. These statements relate to future events or to Health In Tech’s future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause Health In Tech’s actual results, levels of activity, performance, or achievements to be different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond Health In Tech’s control and which could, and likely will, affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects Health In Tech’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to Health In Tech’s operations, results of operations, growth strategy and liquidity.

About Health In Tech 

Health In Tech (Nasdaq: “HIT”) is an Insurtech platform company backed by third-party AI technology, which offers a marketplace that aims to improve processes in the healthcare industry through vertical integration, process simplification, and automation. By removing friction and complexities, we streamline the underwriting, sales and service process for insurance companies, licensed brokers, and TPAs. Learn more at healthintech.com.

 

Health In Tech, Inc.

Consolidated Statements of Operations 

Unaudited 

Three Months Ended

September 30,

Nine Months Ended

 September 30,

2025

2024

2025

2024

Revenues

    Revenues from underwriting

    modeling (ICE)

$1,389,604

$1,528,451

$5,832,164

$4,952,191

    Revenues from fees

7,100,489

2,930,470

19,986,762

9,634,151

       SMR

7,100,489

2,250,549

19,986,762

7,379,016

       HI Card

679,921

2,255,135

Total revenues

8,490,093

4,458,921

25,818,926

14,586,342

Cost of revenues

3,346,277

979,628

9,009,841

2,944,266

Gross profit

5,143,816

3,479,293

16,809,085

11,642,076

Operating expenses

    Sales and marketing expenses

962,567

508,467

3,279,560

2,526,197

    General and administrative expenses

3,451,907

1,813,520

10,474,125

5,629,393

    Research and development expenses

235,819

718,424

1,356,149

2,180,246

Total operating expenses

4,650,293

3,040,411

15,109,834

10,335,836

Other income (expense):

    Interest income

111,699

38,460

305,263

94,111

    Interest expenses

(165,000)

(495,000)

    Other income

157,156

118,399

157,156

    Other expense

(5,000)

(62,759)

(5,000)

(62,759)

Total other income (expense), net

106,699

(32,143)

418,662

(306,492)

Income before income tax expense

$600,222

$406,739

$2,117,913

$999,748

Provision for income taxes

(148,046)

(30,653)

(536,514)

(185,119)

Net income

$452,176

$376,086

$1,581,399

$814,629

Net income per share

    Basic

$0.01

$0.01

$0.03

$0.02

    Diluted

$0.01

$0.01

$0.03

$0.02

Weighted average common stocks outstanding

    Basic

56,432,407

51,769,358

55,484,860

51,769,358

    Diluted

58,774,334

51,769,358

57,477,873

51,769,358

 

Health In Tech, Inc.

Consolidated Balance Sheets

(Unaudited)

September 30, 2025

December 31, 2024

Assets 

Current assets

    Cash

$8,023,613

$7,849,248

    Accounts receivable, net

868,628

1,647,103

    Other receivables

3,871,106

500,252

    Deferred offering costs

166,012

    Prepaid expenses and other current assets

2,117,854

787,161

Total current assets

15,047,213

10,783,764

Non-current assets

    Software

6,182,691

3,962,461

    Loans receivable, net

863,996

815,995

    Operating lease – right of use assets

157,122

206,269

    Long-term prepaid expenses

504,822

Total non-current assets

7,708,631

4,984,725

Total assets

$22,755,844

$15,768,489

Liabilities and stockholders’ equity

Current liabilities

    Accounts payable and accrued expenses

$4,295,384

$1,858,840

 Income taxes payable

205,253

 Operating lease liabilities – current

73,769

66,881

    Other current liabilities

869,088

Total current liabilities

5,238,241

2,130,974

Non-current liabilities

 Deferred tax liabilities

274,809

328,676

 Operating lease liabilities – non-current

83,831

139,811

Total non-current liabilities

358,640

468,487

Total liabilities

5,596,881

2,599,461

Stockholders’ equity

     Common stock, $0.001 par value; Class A Common   

     stock 150,000,000 shares authorized, 44,785,771  

     and 42,914,870 shares issued and outstanding as of

     September 30, 2025 and December 31, 2024,  

     respectively

44,785

42,915

     Common stock, $0.001 par value; Class B Common

     stock 50,000,000 shares authorized, 11,700,000

     shares issued and outstanding as of September 30,   

     2025 and December 31, 2024, respectively

11,700

11,700

  Additional paid-in capital

11,579,683

9,173,017

  Retained earnings

5,522,795

3,941,396

Total stockholders’ equity

17,158,963

13,169,028

Total liabilities and stockholders’ equity

$22,755,844

$15,768,489

 

 Health In Tech, Inc.

  Consolidated Statements of Cash Flows

(Unaudited)

Three Months Ended

September 30,

Nine Months Ended

September 30,

2025

2024

2025

2024

CASH FLOWS FROM OPERATING

ACTIVITIES:

Net income

$452,176

$376,086

$1,581,399

$814,629

Adjustments to reconcile net income to

net cash provided by operating

activities:

    Write-off of accounts receivable

(4,089)

1,901

    Amortization expense

217,981

135,584

489,947

405,158

    Provision for refund liability

1,413,345

2,369,088

    Deferred tax expenses (benefits)

12,680

(27,676)

(53,867)

(86,992)

    Amortization of debt discount

165,000

495,000

    Interest income

(16,003)

(15,999)

(48,001)

(47,997)

    Stock-based compensation expense

292,552

1,493,686

    Changes in operating assets and

    liabilities:

        Accounts receivable, net

416,592

524,838

776,574

1,302,733

        Other receivables

(16,272)

546,645

(3,370,854)

1,166,017

        Prepaid expenses and other current assets

(486,424)

(118,116)

(690,665)

(209,841)

        Long-term prepaid expenses

151,000

(206,666)

        Operating lease right of use assets  

        and liabilities, net

18

624

55

1,871

        Accounts payable and accrued expenses

(224,639)

491,031

2,045,258

(1,064,527)

        Income taxes payable

(34,944)

43,030

(205,253)

(68,675)

        Other current liabilities

(1,500,000)

(1,500,000)

Net cash provided by operating activities

673,973

2,121,047

2,682,602

2,707,376

CASH FLOWS FROM INVESTING

ACTIVITIES:

    Development of software

(744,841)

(67,278)

(2,358,213)

(294,634)

Net cash used in investing activities

(744,841)

(67,278)

(2,358,213)

(294,634)

CASH FLOWS FROM FINANCING

ACTIVITIES:

    Payments of deferred offering costs

(43,685)

(324,744)

(150,024)

(936,864)

    Repayments of notes payable

(2,145,000)

(2,145,000)

Net cash used in financing activities

(43,685)

(2,469,744)

(150,024)

(3,081,864)

Increase (decrease) in cash

(114,553)

(415,975)

174,365

(669,122)

Cash, beginning of the period

8,138,166

2,163,203

7,849,248

2,416,350

Cash, end of the period

8,023,613

1,747,228

8,023,613

1,747,228

Supplemental disclosures of cash flow

information:

Cash paid for interest

$-

$-

$-

$-

Cash paid for income taxes

$198,000

$15,300

$823,323

$340,787

Summary of noncash investing and financing activities:

Accrued deferred offering costs included

in accounts payable and accrued expenses

$55,827

$137,325

$55,827

$137,325

Accrued development of software

included in accounts payable and accrued expenses

$401,964

$126,977

$401,964

$126,977

Issuance of Class A common stock for future service

$146,816

$-

$1,184,800

$-

 

Adjusted EBITDA Reconciliation

(Unaudited)

For Three Months Ended September 30,

For Nine Months Ended September 30,

2025

2024

2025

2024

Net income

$452,176

$376,086

$1,581,399

$814,629

Interest (income) expenses

(111,699)

126,540

(305,263)

400,889

Depreciation and amortization

217,981

135,584

489,947

405,158

Income tax expense

148,046

30,653

536,514

185,119

Stock-based compensation expense

292,552

1,493,686

Total net adjustments

546,880

292,777

2,214,884

991,166

Adjusted EBITDA

$999,056

$668,863

$3,796,283

$1,805,795

Components of Operating Results

Revenues

While we generate our revenue primarily from small employers and insurance carriers, we grow our business primarily from offering solutions that streamline sales processes, enhance service delivery, and reduce the sales cycle duration for TPAs, MGUs, and Brokers. We offer our services through our three subsidiaries. Program services provided by SMR and MGU activities provided by ICE (including eDIYBS) are interdependent, as they cannot function effectively without being combined. Services provided by HI Card are an optional add-on to our other services, and cannot be offered on a standalone basis. Brokers that utilize the program services on behalf of the small employer provided by SMR and MGU activities provided by ICE, are not obligated to utilize our HI Card service. Currently ICE does not offer underwriting services as a standalone service. In the future, we may consider offering it as a standalone service.

Cost of revenues

Cost of revenues primarily consists of infrastructure costs to operate our platform such as hosting fees and fees paid to various third-party partners for access to their technology, services and amortization expenses of our capitalized internal-use software related to our platform. We mainly outsource captive management services and data services from the third-party companies. Our internal proprietary system seeks to consistently improve underwriting and services results through machine learning and data feeds. The captive management activities include introducing new carriers, conducting due diligence on carriers, conducting feasibility studies to determine the viability to be a stop-loss carrier on the platform, negotiating terms and contracts, coordinating audit requests, managing relationship with unrelated carriers and their regulators and auditor firms to ensure that our risk associated with our service offerings is minimized.

Sales and marketing expenses

Sales and marketing expenses primarily consist of personnel-related costs including salaries, stock-based compensation expense, benefits and commissions cost for our sales and marketing personnel. Sales and marketing expenses also include the costs for advertising, promotional and other marketing activities, as well as certain fees paid to various third-party for sales and customer acquisition.

General and administrative expenses

General and administrative expenses primarily consist of personnel-related costs and related expenses for our executives, finance, legal, human resources, technical support, and administrative personnel as well as the costs associated with professional fees for external legal, accounting and other consulting services, insurance premiums.

Research and development expenses

Research and development expenses primarily consist of personnel-related costs, including salaries, stock-based compensation expense and benefits for our research and development personnel. Additional expenses include costs related to the software development, quality assurance, and testing of new technology, and enhancement of our existing platform technology.

Adjusted EBITDA

Adjusted EBITDA represents our net income before net interest expense, taxes, and depreciation and amortization expense, adjusted to eliminate stock-based compensation expense. Adjusted EBITDA is not a measure calculated in accordance with United States Generally Accepted Accounting Principles, or GAAP. We exclude certain non-recurring or non-cash items when calculating Adjusted EBITDA, and we believe this approach provides a more meaningful measure by offering a clearer view of our underlying operational performance.

 

Financial Results Summary

(Unaudited

($ in millions)

Three Months Ended September 30,

Nine Months Ended September 30,

2025

2024

% Change

2025

2024

% Change

Total revenues

$

8.5

$

4.5

90.4 %

$

25.8

$

14.6

77.0 %

GAAP gross margin

60.6 %

78.0 %

-17.4 %

$

65.1 %

$

79.8 %

-14.7 %

Income before income

tax expense

$

0.6

$

0.4

47.6 %

$

2.1

$

1.0

111.8 %

Adjusted EBITDA

$

1.0

$

0.7

49.4 %

$

3.8

$

1.8

110.2 %

Investor Contact
Investor Relations:
ir@healthintech.com

Matter 1.4 Elevates the Linkind Smart Bulb Experience

LOS ANGELES, Nov. 11, 2025 /PRNewswire/ — Linkind is upgrading its range of Matter-enabled smart bulbs with Matter 1.4—the latest version of the industry-unifying smart home protocol. This update delivers meaningful improvements in speed, stability, and ecosystem integration, making your Linkind smart bulbs simpler to pair, easier to use, and more powerful than ever.

Among the benefits of upgrading to Matter 1.4 is support for Adaptive Lighting when using your bulbs with Apple Home. This enables automatic color temperature shifts that follow your daily rhythm—from energizing cool tones in the morning to relaxing warm light at night. It’s a subtle but powerful enhancement that improves comfort, focus, and overall wellbeing.


The update also refines how Linkind bulbs are recognized and managed across popular platforms like Google Home, Alexa, and Apple Home. Expect faster pairing, improved responsiveness, and smoother automation performance. For multi-user homes, enhanced multi-admin support ensures that everyone stays connected and in control.

This upgrade is part of Linkind’s ongoing commitment to open standards, cross-platform compatibility, and lighting that works beautifully—no matter which ecosystem you’re in.

Firmware updates will be delivered over-the-air to all eligible Linkind Matter smart bulbs, bringing the benefits of Matter 1.4 home with zero hassle.

Availability

RGBTW Bulb A19
RGBTW Bulb BR30

More Linkind Matter 1.4 smart light bulbs are coming soon! Visit linkind.com for details.

About Linkind

Linkind, a brand of AiDot, is passionate about lighting your spaces in intelligent and meaningful ways, all while adopting the dedication to innovation and eco-conscious design instilled by its parent company, and overall ecosystem, AiDot. These tenants have guided Linkind from the start and are why they are now able to proudly offer solutions to match any and all residential scenes, such as smart solar-powered solutions that light the path to your home, TV backlighting that takes movie night to the next level, and easy-to-use everyday lighting with unmatched user convenience. Linkind is lighting the way to a brighter tomorrow.

Phoenix Aviation Capital and AIP Capital Announce Issuance of a $592 Million Term Loan Facility

DUBLIN and STAMFORD, Conn. and NEW YORK, Nov. 11, 2025 /PRNewswire/ — Phoenix Aviation Capital (“Phoenix” or “the Company”), a full-service aircraft lessor managed by AIP Capital (“AIP”), an alternative investment manager focused on opportunities in asset-based finance and a portfolio company of funds advised or controlled by affiliates of BC Partners Advisors L.P., announced the issuance of a $592 million term loan facility (“term loan”). Phoenix and AIP intend on using proceeds from the term loan to repay existing warehouse debt and finance future growth.

Morgan Stanley, Citi, and RBC Capital Markets acted as Joint Lead Arrangers and Joint Bookrunners with Morgan Stanley also acting as Administrative Agent and Collateral Agent.

Since the beginning of 2025, Phoenix has raised over $2 billion in bank and institutional capital to support Phoenix’s growth strategy.

“The issuance of this term loan facility provides Phoenix with longer-term flexibility as it continues to grow its portfolio of in-demand aviation assets,” said Jared Ailstock, Managing Partner at AIP. “We also believe the issuance of this facility demonstrates further confidence in Phoenix’s strategy among Phoenix’s lending counterparties.”

“This issuance reflects another key milestone in Phoenix’s execution of its strategy of growing its fleet of next-generation aircraft assets,” said Patrick Schafer, Partner at BC Partners and board member of Phoenix. “The facility will provide Phoenix with additional capacity and flexibility to execute on this strategy.”

Clifford Chance served as transaction counsel and PwC acted as tax advisor to Phoenix and AIP. McCann Fitzgerald also acted in capacity as Irish counsel to Phoenix and AIP. Pivotal Corporate provided corporate services assistance to Phoenix and AIP. Cahill Gordon & Reindel LLP served as transaction counsel to the lenders.

About Phoenix Aviation Capital
Phoenix Aviation Capital is a full-service aircraft lessor focused on financing modern, in-demand aircraft and is dedicated to meeting the financing needs of its airline customers across the globe. Phoenix Aviation Capital is based in Dublin and is managed by AIP Capital, a global aviation asset management and investment firm.

For more information about Phoenix Aviation Capital or to speak with company executives, please contact investor.relations@phoenixaviationcap.com.

About AIP Capital
AIP Capital (AIP) is a global alternative investment manager focused on opportunities in asset-based finance including aviation and equipment finance. AIP, together with its affiliates, manages approximately $4 billion of assets on behalf of a diversified global investor base. The AIP team is comprised of more than 50 experienced professionals across AIP’s offices in Stamford, New York City, Dublin, and Singapore. For more information about AIP Capital or to speak with company executives, please contact investor.relations@aipcapital.com.

About BC Partners & BC Partners Credit
BC Partners is a leading international investment firm in private equity, private debt, and real estate strategies. BC Partners Credit was launched in February 2017, with a focus on identifying attractive credit opportunities in any market environment, often in complex market segments. The platform leverages the broader firm’s deep industry and operating resources to provide flexible financing solutions to middle-market companies across Business Services, Industrials, Healthcare and other select sectors. For further information, visit www.bcpartners.com/credit-strategy.

Media Contacts

AIP Capital Geoffrey Bayers
investor.relations@aipcapital.com

BC Partners
Luke Charalambous
Luke.Charalambous@BCPartners.com
+44 7775 180 721